Research Analysts Offer Predictions for MMSI Q1 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Research analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Merit Medical Systems in a note issued to investors on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings of $0.76 per share for the quarter, down from their prior forecast of $0.81. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q2 2025 earnings at $0.96 EPS, Q4 2025 earnings at $1.02 EPS, Q1 2026 earnings at $0.74 EPS, Q2 2026 earnings at $1.08 EPS, Q3 2026 earnings at $1.10 EPS, Q4 2026 earnings at $1.15 EPS and FY2027 earnings at $4.34 EPS.

MMSI has been the subject of a number of other research reports. Canaccord Genuity Group dropped their price objective on Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Wells Fargo & Company dropped their target price on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Barrington Research dropped their price objective on shares of Merit Medical Systems from $115.00 to $111.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Raymond James increased their price target on Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Tuesday, December 31st. Finally, Piper Sandler reissued an “overweight” rating and issued a $116.00 target price (up from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $110.78.

Merit Medical Systems Stock Performance

Shares of MMSI opened at $101.28 on Thursday. The business has a 50-day simple moving average of $103.82 and a two-hundred day simple moving average of $100.71. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. The stock has a market cap of $5.96 billion, a price-to-earnings ratio of 49.65, a PEG ratio of 2.34 and a beta of 0.91. Merit Medical Systems has a 52 week low of $70.70 and a 52 week high of $111.45.

Institutional Trading of Merit Medical Systems

A number of hedge funds have recently added to or reduced their stakes in MMSI. Barclays PLC boosted its holdings in Merit Medical Systems by 305.4% in the 3rd quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier’s stock worth $11,142,000 after buying an additional 84,923 shares during the last quarter. EULAV Asset Management increased its stake in Merit Medical Systems by 400.0% during the fourth quarter. EULAV Asset Management now owns 115,000 shares of the medical instruments supplier’s stock worth $11,123,000 after acquiring an additional 92,000 shares during the last quarter. Fisher Asset Management LLC raised its position in Merit Medical Systems by 3.2% in the third quarter. Fisher Asset Management LLC now owns 221,690 shares of the medical instruments supplier’s stock valued at $21,910,000 after purchasing an additional 6,837 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Merit Medical Systems by 85.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier’s stock valued at $56,921,000 after purchasing an additional 265,648 shares during the last quarter. Finally, AMI Asset Management Corp grew its holdings in shares of Merit Medical Systems by 28.7% during the 4th quarter. AMI Asset Management Corp now owns 33,041 shares of the medical instruments supplier’s stock worth $3,196,000 after purchasing an additional 7,367 shares during the period. 99.66% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Raul Jr. Parra sold 12,451 shares of the business’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the transaction, the chief financial officer now directly owns 24,201 shares in the company, valued at $2,391,300.81. The trade was a 33.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Brian G. Lloyd sold 25,000 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $99.50, for a total transaction of $2,487,500.00. Following the completion of the transaction, the insider now directly owns 38,993 shares of the company’s stock, valued at approximately $3,879,803.50. This represents a 39.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,132 shares of company stock worth $11,139,521 in the last three months. Corporate insiders own 3.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.